.png){kind=icon}
返回
Missing Novelty in Drug Development
.png){kind=icon}
OA
AI
DOI：10.1093/rfs/hhab024.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
We provide evidence that risk aversion leads pharmaceutical firms to underinvest in radical innovation. We introduce a new measure of drug novelty based on chemical similarity and show that firms face a risk-reward trade-off: novel drug candidates are less likely to obtain FDA approval but are based on more valuable patents. Consistent with a simple model of costly external finance, we show that a positive shock to firms' net worth leads firms to develop more novel drugs. This suggests that even large firms may behave as though they are risk averse, reducing their willingness to investment in potentially valuable radical innovation.
Keyword:
RESEARCH-AND-DEVELOPMENT
MEDICARE-PART-D
MARKET-SIZE
FINANCING INNOVATION
CORPORATE-INVESTMENT
CHEMICAL SIMILARITY
FIRMS
DETERMINANTS
GROWTH
RATES
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
5.4
论文数:
2.8K
被引数:
3.0W
机构
引用论文
Computer‐assisted Interventions Targeting Reading Skills of Children with Reading Disabilities – A Longitudinal Study.png)
Dyslexia
DyslexiaIF0
PREAI
分享收藏A Unified Theory of Tobin's q, Corporate Investment, Financing, and Risk ManagementJOURNAL OF FINANCEOAAI
JOURNAL OF FINANCEIF9.5
OAAI分享收藏
查看更多内容